ASCO 2023 | Phase I dose-escalation study of the BET inhibitor INCB057643 in R/R myelofibrosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the safety results of a Phase I dose-finding study evaluating the BET inhibitor INCB057643 as monotherapy in patients with advanced myeloid malignancies, and in combination with ruxolitinib in patients with relapsed/refractory (R/R) myelofibrosis (MF; NCT04279847). The drug was well tolerated at starting doses and is now being evaluated at 10 mg in the monotherapy arm and 6 mg in the combination arm. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
